IBDEI0E0 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18758,2)
 ;;=^334036
 ;;^UTILITY(U,$J,358.3,18759,0)
 ;;=286.9^^117^1097^9
 ;;^UTILITY(U,$J,358.3,18759,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18759,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,18759,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,18759,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,18760,0)
 ;;=446.6^^117^1097^26
 ;;^UTILITY(U,$J,358.3,18760,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18760,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,18760,1,8,0)
 ;;=8^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,18760,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,18761,0)
 ;;=451.9^^117^1097^25
 ;;^UTILITY(U,$J,358.3,18761,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18761,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,18761,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,18761,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,18762,0)
 ;;=287.5^^117^1097^23
 ;;^UTILITY(U,$J,358.3,18762,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18762,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,18762,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,18762,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,18763,0)
 ;;=287.30^^117^1097^21
 ;;^UTILITY(U,$J,358.3,18763,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18763,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,18763,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,18763,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,18764,0)
 ;;=238.71^^117^1097^24
 ;;^UTILITY(U,$J,358.3,18764,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18764,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,18764,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,18764,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,18765,0)
 ;;=286.53^^117^1097^4
 ;;^UTILITY(U,$J,358.3,18765,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18765,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,18765,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,18765,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,18766,0)
 ;;=286.0^^117^1097^7
 ;;^UTILITY(U,$J,358.3,18766,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18766,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,18766,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,18766,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,18767,0)
 ;;=286.1^^117^1097^5
 ;;^UTILITY(U,$J,358.3,18767,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18767,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,18767,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,18767,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,18768,0)
 ;;=286.2^^117^1097^8
 ;;^UTILITY(U,$J,358.3,18768,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18768,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,18768,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,18768,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,18769,0)
 ;;=286.3^^117^1097^6
 ;;^UTILITY(U,$J,358.3,18769,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18769,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,18769,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,18769,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,18770,0)
 ;;=286.4^^117^1097^28
 ;;^UTILITY(U,$J,358.3,18770,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18770,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,18770,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,18770,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,18771,0)
 ;;=286.52^^117^1097^2
 ;;^UTILITY(U,$J,358.3,18771,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18771,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,18771,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,18771,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,18772,0)
 ;;=286.59^^117^1097^16
 ;;^UTILITY(U,$J,358.3,18772,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18772,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,18772,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,18772,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,18773,0)
 ;;=286.6^^117^1097^10
 ;;^UTILITY(U,$J,358.3,18773,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18773,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,18773,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,18773,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,18774,0)
 ;;=286.7^^117^1097^1
 ;;^UTILITY(U,$J,358.3,18774,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18774,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,18774,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,18774,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,18775,0)
 ;;=287.0^^117^1097^3
 ;;^UTILITY(U,$J,358.3,18775,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18775,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,18775,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,18775,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,18776,0)
 ;;=287.1^^117^1097^22
 ;;^UTILITY(U,$J,358.3,18776,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18776,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,18776,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,18776,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,18777,0)
 ;;=287.2^^117^1097^17
 ;;^UTILITY(U,$J,358.3,18777,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18777,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,18777,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,18777,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,18778,0)
 ;;=287.31^^117^1097^13
 ;;^UTILITY(U,$J,358.3,18778,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18778,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,18778,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,18778,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,18779,0)
 ;;=287.32^^117^1097^11
 ;;^UTILITY(U,$J,358.3,18779,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18779,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,18779,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,18779,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,18780,0)
 ;;=287.41^^117^1097^20
 ;;^UTILITY(U,$J,358.3,18780,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18780,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,18780,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,18780,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,18781,0)
 ;;=287.49^^117^1097^18
 ;;^UTILITY(U,$J,358.3,18781,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18781,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,18781,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,18781,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,18782,0)
 ;;=287.8^^117^1097^19
 ;;^UTILITY(U,$J,358.3,18782,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18782,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,18782,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,18782,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,18783,0)
 ;;=287.9^^117^1097^27
 ;;^UTILITY(U,$J,358.3,18783,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18783,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,18783,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,18783,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,18784,0)
 ;;=238.72^^117^1097^14
 ;;^UTILITY(U,$J,358.3,18784,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18784,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,18784,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,18784,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,18785,0)
 ;;=238.73^^117^1097^12
 ;;^UTILITY(U,$J,358.3,18785,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18785,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,18785,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,18785,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,18786,0)
 ;;=238.75^^117^1097^15
 ;;^UTILITY(U,$J,358.3,18786,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18786,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,18786,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,18786,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,18787,0)
 ;;=205.00^^117^1098^32
 ;;^UTILITY(U,$J,358.3,18787,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18787,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,18787,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18787,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,18788,0)
 ;;=205.01^^117^1098^31
 ;;^UTILITY(U,$J,358.3,18788,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18788,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,18788,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18788,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,18789,0)
 ;;=205.10^^117^1098^18
 ;;^UTILITY(U,$J,358.3,18789,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18789,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,18789,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18789,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,18790,0)
 ;;=205.11^^117^1098^17
 ;;^UTILITY(U,$J,358.3,18790,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18790,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,18790,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18790,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,18791,0)
 ;;=289.0^^117^1098^50
 ;;^UTILITY(U,$J,358.3,18791,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18791,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,18791,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,18791,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,18792,0)
 ;;=238.4^^117^1098^48
 ;;^UTILITY(U,$J,358.3,18792,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18792,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,18792,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,18792,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,18793,0)
 ;;=288.9^^117^1098^67
 ;;^UTILITY(U,$J,358.3,18793,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18793,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,18793,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,18793,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,18794,0)
 ;;=289.81^^117^1098^49
 ;;^UTILITY(U,$J,358.3,18794,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18794,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,18794,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,18794,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,18795,0)
 ;;=238.75^^117^1098^29
